Astellas/Medivation raise prostate cancer stakes as Xtandi PREVAILS in broader population
This article was originally published in Scrip
Executive Summary
Astellas/Medivation's prostate cancer treatment Xtandi (enzalutamide) appears to have sailed through a major test to its commercial success – showing efficacy in chemotherapy-naïve patients that rivals that of its chief competitor, Zytiga (Johnson & Johnson's abiraterone).